5-HT6 Receptor Antagonist as an Adjunct Treatment Targeting Residual Symptoms in Patients With Schiz

IPHARMA article "5-HT6 Receptor Antagonist as an Adjunct Treatment Targeting Residual Symptoms in Patients With Schizophrenia: Unexpected Sex-Related Effects (Double-Blind Placebo-Controlled Trial)" has been published in the "Journal of Clinical Psychopharmacology".

Treating patients who experience residual psychotic symptoms during remission of schizophrenia remains one of the most challenging problems. The mechanisms underlying these symptoms differ from those of acute hallucinations and delusions. 5-HT6 receptor antagonists have been considered promising agents in treatment of residual psychotic symptoms and cognitive dysfunction. The aim of the study was to assess the efficacy of a selective 5-HT6 inhibitor Avisetron in the reduction of residual psychotic symptoms in patients with schizophrenia on stable antipsychotic therapy.

Eighty clinically stable outpatient subjects with schizophrenia with residual psychotic symptoms were randomized in a double-blind manner to 6 weeks of Avisetron or placebo at 1:1 ratio. Subjects received 8 mg of Avisetron or placebo on top their stable antipsychotic treatment. Standard clinical scales and cognitive tests were used for endpoint assessment. The primary efficacy endpoint was the mean reduction of total Positive and Negative Syndrome Scale score after 6 weeks of treatment.


Vostokova, Natalia, PharmD

Morozova, Margarita MD, PhD

Burminskiy, Denis MD

Rupchev, George PhD

Lepilkina, Taissia MPsych

Potanin, Sergey MD, PhD

Beniashvili, Allan MD, PhD

Lavrovsky, Yan MD, PhD

Ivaschenko, Alexander PhD

*From the Mental Health Research Center, Moscow, Russia; R-Pharm Overseas, Inc, San Diego, CA; IPHARMA LLC (ChemRar/ChemDiv group), Moscow, Russia; ChemDiv, San-Diego, CA.


#schizophrenia #psychiatry #avisetron

Недавние посты